Anthoula Koliadi
PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Gustav Ullenhag
- Mobile phone:
- +46 70 971 68 70
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Specialist physician at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Ingrid Glimelius
- Mobile phone:
- +46 70 971 68 70
- E-mail:
- anthoula.koliadi@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Short presentation
Senior Consultant in Gynecological Oncology. In charge of the section of Gynecological Oncology at the Oncology Department, Akademiska Sjukhuset, Uppsala, Sweden
Keywords
- cervixcancer
- strålbehandling
- brachyterapi
- tumörbiologi

Publications
Recent publications
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Part of Cancer Causes and Control, p. 1101-1109, 2024
- DOI for Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
- Download full text (pdf) of Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, Singapore, May 04-09, 2024, 2024
Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, 2024
Part of Abstracts - 30th European Symposium on Urogenital Radiology, 2024
All publications
Articles in journal
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
- Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Part of Cancer Causes and Control, p. 1101-1109, 2024
- DOI for Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
- Download full text (pdf) of Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Part of Cancer Causes and Control, p. 1101-1109, 2024
- DOI for Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
- Download full text (pdf) of Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Part of Frontiers in Oncology, 2024
- DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
- Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
Part of Pigment Cell & Melanoma Research, 2024
- DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
- Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Part of Cancer Medicine, p. 13217-13224, 2023
- DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
- Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
Part of International Journal of Cancer, p. 773-781, 2022
- DOI for Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
- Download full text (pdf) of Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
Part of Oncoimmunology, 2021
- DOI for Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
- Download full text (pdf) of Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
Part of Upsala Journal of Medical Sciences, p. 325-329, 2020
High proliferation is associated with inferior outcome in male breast cancer patients
Part of Modern Pathology, p. 87-94, 2013
Part of International Journal of Cancer, p. 961-967, 2010
Part of Acta Oncologica, p. 816-820, 2010
Comprehensive doctoral thesis
Conference papers
Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, Singapore, May 04-09, 2024, 2024
Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, 2024
Part of Abstracts - 30th European Symposium on Urogenital Radiology, 2024